Daratumumab-Based Therapeutic Approaches and Clinical Outcomes in Multiple Myeloma and other Plasma Cell Dyscrasias: Insights from a Nationwide Real-World Chart Review Study.

22–24 There has been an increasing trend in the upfront use of daratumumab-based quadruplets 25–29 to achieve minimal residual disease (MRD) negative status, which is considered a surrogate marker for improved OS 30 and PFS. 30–32 Daratumumab is also used in light chain amyloidosis (AL) 33 and other plasma cell disorders. 34–38 Although a

also in 63,971 other papers